Comparative Pharmacology
Head-to-head clinical analysis: CLISTIN versus PROMETHAZINE VC PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLISTIN versus PROMETHAZINE VC PLAIN.
CLISTIN vs PROMETHAZINE VC PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clistin (histamine-1 receptor antagonist) competitively blocks histamine at H1 receptor sites, inhibiting vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), sedative, antiemetic, and anticholinergic effects. Phenylephrine is a sympathomimetic amine acting primarily on alpha-1 adrenergic receptors, causing vasoconstriction.
4 mg orally every 4-6 hours as needed; maximum 24 mg/day.
Adults: 1 tablet (promethazine 6.25 mg, phenylephrine 10 mg) orally every 4-6 hours as needed, not to exceed 4 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In patients with renal impairment, half-life may be prolonged, requiring dose adjustment.
Terminal elimination half-life is approximately 9–16 hours (mean ~12 hours) in adults; may be prolonged in hepatic impairment or elderly patients.
Primarily renal excretion (approximately 85-90% as unchanged drug and metabolites). Biliary/fecal elimination accounts for the remainder (10-15%).
Primarily renal as inactive metabolites; approximately 70-80% excreted in urine, with about 20-30% in feces via biliary secretion. Less than 1% excreted unchanged.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic